Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Instagram Outage Disrupts Thousands of U.S. Users 
PHILADELPHIA and OXFORD, United Kingdom, March 02, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday March 7, 2017 at 10:40-11:10 AM EST (3:40-4:10 PM GMT). The conference is being held at the Boston Marriott Copley Plaza. Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
Adaptimmune Contacts Investor Relations Will Roberts T: (215) 825-9306 E: [email protected] Juli P. Miller, Ph.D. T: (215) 825-9310 E: [email protected] Media Relations Margaret Henry T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: [email protected]
